News
LJUIF
0.540
NaN%
--
SSY Group (LJUIF) Receives a Buy from Huatai Securities
TipRanks · 2d ago
SSY Group Wins China Approval for Upadacitinib Bulk Drug
TipRanks · 2d ago
SSY Group Wins China Approval for New Irrigation and Bumetanide Injectables
TipRanks · 5d ago
SSY Group FY25 Profit Drops On Weak Revenues; Cuts Dividend- Update
NASDAQ · 6d ago
SSY Group Profit Halves as Revenue and Margins Slide in Challenging 2025
TipRanks · 6d ago
SSY Group Declares Final Cash Dividend of HKD 0.03 per Share for 2025
TipRanks · 6d ago
SSY Group Wins First PRC Approval for New Fat-Soluble Vitamin Injection
TipRanks · 03/13 09:16
SSY Group Wins China Approval for Homegrown High-Performance Infusion Tubing
TipRanks · 03/13 08:43
SSY Group Wins China Approval for New Oncology Injection
TipRanks · 03/06 04:19
SSY Group Wins First-in-China Approval for Doxapram Injection
TipRanks · 03/03 04:10
SSY Group Wins Hebei Approval for Gynecological Gel and Heart Failure Test Kit
TipRanks · 02/27 09:50
SSY Group Issues Profit Warning as Pricing and Demand Pressures Hit 2025 Earnings
TipRanks · 02/16 09:07
SSY Group Wins China Approval for Propranolol Bulk Drug
TipRanks · 02/13 04:38
SSY Group Wins 45 Drug Selections in China’s National Centralised Procurement Renewal
TipRanks · 02/10 09:25
SSY Group Wins NMPA Approvals for Two New Bulk Drug Products
TipRanks · 02/09 10:37
SSY Group Wins NMPA Approval for New Cardiac Injection
TipRanks · 01/30 04:16
SSY Group Wins China Approval for New Specification of Nutritional Injection
TipRanks · 01/26 09:37
SSY Group Wins China Approval for New Hypertension Combination Drug
TipRanks · 01/05 09:39
SSY Group Wins NMPA Approval for Sodium Glycerophosphate Injection
TipRanks · 12/29/2025 00:37
SSY Group Renews Key Connected Transactions with Sichuan Kelun for 2026
TipRanks · 12/23/2025 09:41
More
Webull provides a variety of real-time LJUIF stock news. You can receive the latest news about Ssy Group through multiple platforms. This information may help you make smarter investment decisions.
About LJUIF
SSY Group Ltd, formerly known as Lijun International Pharmaceutical Holding Co Ltd, is an investment holding company principally engaged in the research, development, manufacture and sale of pharmaceutical products. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.